Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chronic Myelocytic Leukemia
Company obtains orphan drug designation for c-Myb Antisense (LR3001) in CML
April 14th, 2005
Genta, Inc., (GNTA) announced that LR3001, an antisense compound directed against a gene known as c-Myb, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of chronic myelocytic leukemia (CML). Designation as an orphan drug, which is intended to facilitate product development, provides eligibility for a 7-year period of market exclusivity after approval, grants and tax credits for research and development, and reduced filing fees for marketing applications. Genta obtained rights to LR3001 from Temple University in December 2004. The drug has been tested in two phase I clinical trials in patients...
Source: Women's Health Weekly (2005-04-14)
|
